CN Stock MarketDetailed Quotes

002437 Harbin Gloria Pharmaceuticals

Watchlist
  • 2.45
  • -0.06-2.39%
Market Closed May 9 15:00 CST
5.50BMarket Cap22.90P/E (TTM)

About Harbin Gloria Pharmaceuticals Company

The company was founded in March 2000. Since its launch in 2010, it has been adhering to the “product leading” strategy, and has enriched the company's product line through various methods such as epitaxial mergers and acquisitions, cooperative agents, independent research and development, and overseas introduction, etc., and has expanded from the narrow and single orthopedic treatment field at the beginning of the market to the existing cardiovascular and cerebrovascular treatment fields. A new pattern of multi-product-driven performance growth has gradually emerged. The company is mainly engaged in R&D, production and sales of pharmaceuticals. The company's main products include amlodipine tablets, injectable creatine phosphate, ginkgo damole injections, olmesartan amlodipine tablets, edoxaban toluene sulfonate tablets, pravastatin tablets, deer guanadine injections, sodium hyaluronate injections, multivitamin injections, potassium chloride sustained-release tablets, injectable potassium magnesium aspartate, sitagliptin metformin extended-release tablets, flurbiprofen injections, merogabarine benzenesulfonate tablets, deoxynucleic acid Sodium injection (DNA), levocarnitine injection, compound ammonium glycyrrhizinate S for injection, cephalexide sodium for injection, compound head Faclor capsules, injectable calcium levofolate, fluorouracil for injection, cyclophosphamide for injection, and Pingyangmycin hydrochloride for injection. Corporate honors: In October 2018, Yuheng Pharmaceutical won the title of 2018 China's Top 100 Industrial Enterprises with Comprehensive Strength in the Chemical and Pharmaceutical Industry. In July 2018, Yuheng Pharmaceutical was listed as one of the “Top 100 Pharmaceutical Industries in China”. In June 2018, Yuheng Pharmaceutical won two awards: “2017 China's Top 100 Pharmaceutical Industry” and “2017 China Pharmaceutical Law-abiding and Honest Enterprise”. In May 2018, Yuheng Pharmaceutical won the 2018 Brand Value Assessment Enterprise Brand List, “2022 Top 100 Chinese Chemical Companies”, “Specialized and New” SMEs, “2022 Outstanding Private Enterprises in Datong City”, “2022 Outstanding Tax Contribution Award”, “Outstanding Economic Contribution Enterprise Award”, and “Outstanding Tax Contribution Enterprise Award”.

Company Profile

Short Name-A誉衡药业
Symbol-A002437
Company NameHarbin Gloria Pharmaceuticals Co., Ltd.
Listing DateJun 23, 2010
Issue Price50.00
Shares Offered35.00M share(s)
FoundedMar 27, 2000
Listed ExchangeSZ Stock Exchange
Legal Representativeleifeng guo
General Managerleifeng guo
Secretaryyueyin liu
Accounting FirmShanghui Accounting Firm (Special General Partnership)
Securities Representativexuelong bai
Legal CounselBeijing Jingxuan Law Firm
Employees64
Phone010-80479607
Office AddressBuilding 28, Ronghui Park, Yuhua Road, Area B, Airport Development Zone, Shunyi District, Beijing
Zip Code101318
Registered AddressNo. 29, Beijing Road, Limin Economic and Technological Development Zone, Hulan District, Harbin City, Heilongjiang Province
Fax010-68002438-607
Emailirm@gloria.cc
Business License230000400002254
BusinessProduction and sale of tablets, capsules, granules, powder injections (all cephalosporins), powder injections (hormones), dry suspensions, small-volume injections (including antineoplastic drugs), freeze-dried powder injections (including antineoplastic drugs, cephalosporins), suppositories, raw materials (Qinlongxin, yanhuning, etomidate, flubiprofen ester), imported drugs are packaged separately (injections (sodium hyaluronate injections); technical consultation, process technology transfer, technology development.

Company Executives

  • Name
  • Position
  • Salary
  • zhenyu shen
  • Chairman, Directors, Audit Committee Member, Chairman of the Strategy Committee
  • --
  • yueyin liu
  • Directors, Board Secretary, Deputy General Manager
  • 1.21M
  • kang zhou
  • Directors, Deputy General Manager, Member of the Remuneration and Assessment Committee
  • 2.09M
  • leifeng guo
  • Directors, General Manager, Head of Finance, Nomination Committee Members, Strategy Committee Member
  • 2.16M
  • lida wang
  • Independent Directors, Chairman of the Audit Committee, Nomination Committee Members, Chairman of the Remuneration and Assessment Committee
  • --
  • yi chen
  • Independent Directors, Audit Committee Member, Member of the Remuneration and Assessment Committee, Strategy Committee Member, Chairman of the Nomination Committee
  • --
  • xuelong bai
  • Securities Affairs Representative
  • --
  • chao zhang
  • Chairman of the Supervisory Board, Shareholder Supervisors
  • 14.40K
  • lili shang
  • Shareholder Supervisors
  • 13.70K
  • runbao li
  • Deputy General Manager
  • 1.22M
  • xiaohang wang
  • Deputy General Manager
  • 1.10M
  • wenjie xia
  • Head of Audit
  • --
  • yunlong gao
  • Employee Supervisors
  • --

Market Insights

Warren Buffett Portfolio Warren Buffett Portfolio

Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry. Buffett's holdings are the latest portfolio from Berkshire Hathaway. Regarded as a top investor, his trades often signal the market and influence the industry.

Unlock Now

Discussing

Berkshire 2025 highlights: Stepping aside as CEO, trade and market volatility
$Berkshire Hathaway-A (BRK.A.US)$ held its highly anticipated annual shareholders meeting Saturday. Here are some key takeaways from the eve Show More